Supernus Pharmaceuticals (SUPN) Total Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Liabilities data on file, last reported at $423.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $423.9 million, up 33.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $423.9 million (up 33.9% YoY), and the FY2025 annual result was $390.9 million, up 17.63% from the prior year.
• Total Liabilities improved to $423.9 million in Q1 2026 per SUPN's latest filing, from $390.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $879.7 million in Q1 2023 and troughed at $316.6 million in Q1 2025.
• A 5-year average of $501.4 million and a median of $373.2 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Liabilities plunged 57.38% in 2024, then soared 33.9% in 2026.
• A 5-year view of Total Liabilities shows it stood at $816.3 million in 2022, then plunged by 56.37% to $356.2 million in 2023, then decreased by 6.69% to $332.3 million in 2024, then advanced by 17.63% to $390.9 million in 2025, then climbed by 8.44% to $423.9 million in 2026.
• Business Quant data shows SUPN's Total Liabilities at $423.9 million in Q1 2026, $390.9 million in Q4 2025, and $370.1 million in Q3 2025.